# Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®

> **NCT01277705** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 806 (actual)

## Conditions studied

- Tetanus
- Diphtheria
- Acellular Pertussis

## Interventions

- **BIOLOGICAL:** GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine
- **BIOLOGICAL:** Boostrix™
- **BIOLOGICAL:** GSK Biologicals' IPV vaccine
- **BIOLOGICAL:** Revaxis®

## Key facts

- **NCT ID:** NCT01277705
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2002-04
- **Final completion:** 2002-04
- **Target enrollment:** 806 (ACTUAL)
- **Last updated:** 2016-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01277705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01277705, "Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01277705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*